Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow

Abstract:

:The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal tandem duplication mutated AML, allogeneic hematopoietic stem-cell transplantation (SCT) was commonly performed in first complete remission. Remarkable progress has been made in frontline treatments with the incorporation of FLT3 inhibitors and the development of highly sensitive minimal/measurable residual disease assays. Similarly, recent progress in allogeneic hematopoietic SCT includes improvement of transplant techniques, the use of haploidentical donors in patients lacking an HLA matched donor, and the introduction of FLT3 inhibitors as post-transplant maintenance therapy. Nevertheless, current transplant strategies vary between centers and differ in terms of transplant indications based on the internal tandem duplication allelic ratio and concomitant nucleophos-min-1 mutation, as well as in terms of post-transplant maintenance/consolidation. This review generated by international leukemia or transplant experts, mostly from the European Society for Blood and Marrow Transplantation, attempts to develop a position statement on best approaches for allogeneic hematopoietic SCT for AML with FLT3-internal tandem duplication including indications for and modalities of such transplants and on the potential optimization of post-transplant maintenance with FLT inhibitors.

journal_name

Haematologica

journal_title

Haematologica

authors

Bazarbachi A,Bug G,Baron F,Brissot E,Ciceri F,Dalle IA,Döhner H,Esteve J,Floisand Y,Giebel S,Gilleece M,Gorin NC,Jabbour E,Aljurf M,Kantarjian H,Kharfan-Dabaja M,Labopin M,Lanza F,Malard F,Peric Z,Prebet T,Ravan

doi

10.3324/haematol.2019.243410

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

1507-1516

issue

6

eissn

0390-6078

issn

1592-8721

pii

haematol.2019.243410

journal_volume

105

pub_type

杂志文章
  • Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.

    abstract::It is well known that allo-reactive T cells play a crucial role in graft-versus-leukemia and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (alloSCT). Allo-reactive CD4(+) T cells can mediate direct cytolysis, but may also stimulate production of IgG antibodies as helper cells. Immu...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2013.086652

    authors: Kremer AN,van der Griendt JC,van der Meijden ED,Honders MW,Ayoglu B,Schwenk JM,Nilsson P,Falkenburg JH,Griffioen M

    更新日期:2014-02-01 00:00:00

  • Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm.

    abstract::Acute myeloid leukemia carrying cytoplasmic mutated nucleophosmin (NPMc(+) AML) and blastic plasmacytoid dendritic cell neoplasm have been included as new entities in the 4(th) edition (2008) WHO classification of myeloid neoplasms. These conditions may show clinical and pathological overlapping features (leukemic and...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.13855

    authors: Facchetti F,Pileri SA,Agostinelli C,Martelli MP,Paulli M,Venditti A,Martelli MF,Falini B

    更新日期:2009-02-01 00:00:00

  • A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy.

    abstract:BACKGROUND AND OBJECTIVES:Continuous erythropoietin receptor activator (C.E.R.A.) is an innovative agent with unique erythropoietin receptor activity and a prolonged half-life, which has the potential for administration at extended dosing intervals. The objectives of this dose-finding study were to evaluate the hemoglo...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3324/haematol.10730

    authors: Dmoszynska A,Kloczko J,Rokicka M,Hellmann A,Spicka I,Eid JE

    更新日期:2007-04-01 00:00:00

  • Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.

    abstract:BACKGROUND:Epigenetic changes are involved in the extinction of the B-cell gene expression program of classical Hodgkin's lymphoma. However, little is known regarding epigenetic similarities between cells of classical Hodgkin's lymphoma and plasma cell myeloma, both of which share extinction of the gene expression prog...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.031138

    authors: Seitz V,Thomas PE,Zimmermann K,Paul U,Ehlers A,Joosten M,Dimitrova L,Lenze D,Sommerfeld A,Oker E,Leser U,Stein H,Hummel M

    更新日期:2011-06-01 00:00:00

  • Collection of peripheral blood stem cells by apheresis with continuous flow blood cell separator Dideco Vivacell.

    abstract::In S. Camillo Hospital, Rome, the Apheresis Center (CNTS-CRI) and the Haematological Division, Authors treated 17 patients affected by haematologic malignances and solid tumours with leukoapheresis procedures for PBSC collection. Nine patients were treated with continuous-flow cell separator Dideco Vivacell, performin...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Del Monte C,Basso P,Consoli P,Cossutta M,Morara R,Pescarollo A,Lanti T

    更新日期:1990-01-01 00:00:00

  • Hemophilia therapy: the future has begun.

    abstract::The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. This positive scenario was consolidated in terms of greater safety a...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.232132

    authors: Mannucci PM

    更新日期:2020-03-01 00:00:00

  • Autologous blood stem cell transplantation in hematologic malignancies.

    abstract::Circulating stem cells (CSC) are well documented in animals and humans. Though their function in normal conditions remains obscure, autologous CSC seem capable of restoring hemopoiesis after myeloablative treatment. With cell separators CSC may be harvested in adequate number, and collection may be further improved gi...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Majolino I,Scimé R,Indovina A

    更新日期:1990-11-01 00:00:00

  • Double versus single autotransplantation in multiple myeloma; a single center experience of 100 patients.

    abstract::One hundred patients with newly diagnosed multiple myeloma (MM) were treated with high-dose chemotherapy followed by single or double autologous stem cell transplantation (ASCT). Up-front treatment with a double ASCT tended to prolong progression-free and overall survival. ...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Putkonen M,Rauhala A,Itälä M,Kauppila M,Pelliniemi TT,Remes K

    更新日期:2005-04-01 00:00:00

  • Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome.

    abstract:BACKGROUND AND OBJECTIVES:Myeloid leukemia of Down's syndrome (ML-DS) has characteristic biological features (e.g. expression of the truncated GATA1s), which are different from those of non-DS childhood acute myeloid leukemias (AML). The objective of this study was to investigate factors predisposing to the development...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Langebrake C,Klusmann JH,Wortmann K,Kolar M,Puhlmann U,Reinhardt D

    更新日期:2006-11-01 00:00:00

  • Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.

    abstract:BACKGROUND AND OBJECTIVES:Our objective was to improve the outcome of cord blood (CB) transplantation in adults, by overcoming the limitations imposed by the low number of stem cells present in CB units. DESIGN AND METHODS:We combined single CB units and co-infusion of third party donor (TPD)-derived peripheral blood ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Magro E,Regidor C,Cabrera R,Sanjuán I,Forès R,Garcia-Marco JA,Ruiz E,Gil S,Bautista G,Millán I,Madrigal A,Fernandez MN

    更新日期:2006-05-01 00:00:00

  • Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites.

    abstract::Mucosa-associated lymphoid tissue (MALT) lymphoma originates from a background of diverse chronic inflammatory disorders at various anatomic sites. The genetics underlying its development, particularly in those associated with autoimmune disorders, is poorly characterized. By whole exome sequencing of 21 cases of MALT...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.191601

    authors: Moody S,Thompson JS,Chuang SS,Liu H,Raderer M,Vassiliou G,Wlodarska I,Wu F,Cogliatti S,Robson A,Ashton-Key M,Bi Y,Goodlad J,Du MQ

    更新日期:2018-08-01 00:00:00

  • Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.

    abstract::Effects of concurrent inhibition of mTORC1/2 and Bcl-2/Bcl-xL in human acute myeloid leukemia cells were examined. Tetracycline-inducible Bcl-2/Bcl-xL dual knockdown markedly sensitized acute myeloid leukemia cells to the dual TORC1/2 inhibitor INK128 in vitro as well as in vivo. Moreover, INK128 co-administered with ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2015.130351

    authors: Rahmani M,Aust MM,Hawkins E,Parker RE,Ross M,Kmieciak M,Reshko LB,Rizzo KA,Dumur CI,Ferreira-Gonzalez A,Grant S

    更新日期:2015-12-01 00:00:00

  • A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.

    abstract:BACKGROUND:beta-thalassemia is one of the most common genetic diseases in the world and requires extensive therapy. Lentiviral-mediated gene therapy has been successfully exploited in the treatment of beta-thalassemia and showed promise in clinical application. Using a human beta-globin transgenic mouse line in a beta-...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12010

    authors: Li W,Xie S,Guo X,Gong X,Wang S,Lin D,Zhang J,Ren Z,Huang S,Zeng F,Zeng Y

    更新日期:2008-03-01 00:00:00

  • Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.

    abstract:BACKGROUND AND OBJECTIVE:The outcome of patients with severe aplastic anemia (SAA) has improved considerably over the last decades. Bone marrow transplantation (BMT) is the treatment of choice in young patients who have an HLA-identical sibling donor. This study analyzes the outcome and factors related to survival in p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Hernández-Boluda JC,Marín P,Carreras E,Aguilar JL,Grañena A,Rozman C,Montserrat E

    更新日期:1999-01-01 00:00:00

  • Idarubicin in low-grade non-Hodgkin's lymphomas.

    abstract::The majority of responses produced in patients with low-grade lymphomas are unique among non-Hodgkin's lymphomas (NHL), and even with a more intensive chemotherapy regimen, they are only partial; the very few complete responses which are induced are usually of short duration and do not influence overall survival. Ther...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Zinzani PL

    更新日期:1997-09-01 00:00:00

  • ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells.

    abstract::Successful expansion of hematopoietic stem cells would benefit the use of hematopoietic stem cell transplants in the clinic. Several angiopoietin-like proteins, including angiopoietin-like 7, can support the activity of hematopoietic stem cells. However, effects of ANGPTL7 on human hematopoietic stem cells and the dow...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2014.118612

    authors: Xiao Y,Jiang Z,Li Y,Ye W,Jia B,Zhang M,Xu Y,Wu D,Lai L,Chen Y,Chang Y,Huang X,Liu H,Qing G,Liu P,Li Y,Xu B,Zhong M,Yao Y,Pei D,Li P

    更新日期:2015-05-01 00:00:00

  • Megakaryocyte volume modulates bone marrow niche properties and cell migration dynamics.

    abstract::All hematopoietic cells that develop in the bone marrow must cross the endothelial barrier to enter the blood circulation. Blood platelets, however, are released by bigger protrusions of huge progenitor cells, named megakaryocytes, and enter the blood stream as so-called proplatelets before fragmenting into mature pla...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.202010

    authors: Gorelashvili MG,Angay O,Hemmen K,Klaus V,Stegner D,Heinze KG

    更新日期:2020-04-01 00:00:00

  • Inversion mutation as a major cause of severe hemophilia A in Italian patients.

    abstract::We investigated the presence of a recombinant event between the F8A gene located in intron 22 of the factor VIII gene and the two additional copies of F8A lying 500 Kb upstream of FVIII in severe hemophilic patients. The genomic DNA of 146 unrelated Italian patients with severe hemophilia A (HA) was hybridized with an...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Mori PG,Caprino D,Bicocchi MP,Valetto A,Bottini F,Aquila M

    更新日期:1997-01-01 00:00:00

  • Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.

    abstract::Arecent source data meta-analysis of randomized trials in adults assessing the immunoconjugate gemtuzumab ozogamicin combined with standard chemotherapy in acute myeloid leukemia showed a significant survival benefit in patients without an adverse karyotype. It is not clear whether the optimal dose should be 3 mg/m(2)...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3324/haematol.2016.141937

    authors: Burnett A,Cavenagh J,Russell N,Hills R,Kell J,Jones G,Nielsen OJ,Khwaja A,Thomas I,Clark R,UK NCRI AML Study Group.

    更新日期:2016-06-01 00:00:00

  • Neurological disorders in essential thrombocythemia.

    abstract::Patients with essential thrombocythemia often complain of various subjective neurological symptoms. This prospective study aims to assess their incidence and response to therapy. Among 37 consecutive patients with essential thrombocythemia, 11 presented with neurological symptoms. Among them 4 had thrombotic events, 7...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2011.050005

    authors: Billot S,Kouroupi EG,Le Guilloux J,Cassinat B,Jardin C,Laperche T,Fenaux P,Carpentier AF,Kiladjian JJ

    更新日期:2011-12-01 00:00:00

  • Core needle biopsy is effective in the initial diagnosis of mediastinal lymphoma.

    abstract:BACKGROUND AND OBJECTIVE:With the development and refinement of guidance modalities for percutaneous biopsies, many investigators have reported studies supporting the role of guided core needle biopsy in the diagnosis of mediastinal lymphoma. The aims of this report are to evaluate the efficacy of findings at core need...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Zinzani PL,Corneli G,Cancellieri A,Magagnoli M,Lacava N,Gherlinzoni F,Bendandi M,Albertini P,Baruzzi G,Tura S,Boaron M

    更新日期:1999-07-01 00:00:00

  • Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.

    abstract:BACKGROUND:The c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis and prognosis of many human malignancies. We studied the function and prognostic significance of c-Met and hepatocyte ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.056101

    authors: Xu C,Plattel W,van den Berg A,Rüther N,Huang X,Wang M,de Jong D,Vos H,van Imhoff G,Viardot A,Möller P,Poppema S,Diepstra A,Visser L

    更新日期:2012-04-01 00:00:00

  • Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

    abstract::Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation. Patients with neurofibromatosis type 1 harbor loss-of-function mutations in NF1 and have a 200- to 500-fold increased ri...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2015.136002

    authors: Sachs Z,Been RA,DeCoursin KJ,Nguyen HT,Mohd Hassan NA,Noble-Orcutt KE,Eckfeldt CE,Pomeroy EJ,Diaz-Flores E,Geurts JL,Diers MD,Hasz DE,Morgan KJ,MacMillan ML,Shannon KM,Largaespada DA,Wiesner SM

    更新日期:2016-10-01 00:00:00

  • Knockdown of Hnrnpa0, a del(5q) gene, alters myeloid cell fate in murine cells through regulation of AU-rich transcripts.

    abstract::The control of mRNA stability plays a central role in orchestrating gene-regulatory networks in hematopoietic cell growth, differentiation and tumorigenesis. HNRNPA0, which encodes an RNA-binding protein shown to regulate transcript stability via binding to the AU-rich elements of mRNAs, is located within the commonly...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.098657

    authors: Young DJ,Stoddart A,Nakitandwe J,Chen SC,Qian Z,Downing JR,Le Beau MM

    更新日期:2014-06-01 00:00:00

  • High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.

    abstract:BACKGROUND AND OBJECTIVES:Patients with aggressive non-Hodgkin's lymphomas (NHL) who do not obtain a complete response (CR) after induction chemotherapy have a poor prognosis. However, provided they are sensitive to the first regimen of chemotherapy, 25-40% of them with a B-cell phenotype may achieve long-term survival...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Rodriguez J,Caballero MD,Gutierrez A,Gandarillas M,Sierra J,Lopez-Guillermo A,Sureda A,Zuazu J,Marin J,Arranz R,Carreras E,Leon A,De Sevilla AF,San Miguel JF,Conde E,GEL\/TAMO Spanish Group.

    更新日期:2003-12-01 00:00:00

  • In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.

    abstract:BACKGROUND AND OBJECTIVES:Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacologic approach with antagonists of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex. In this study we assessed the effects of abciximab, a recombinant chimeric Fab fraction of the antibody against GP...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Rossi F,Rossi E,Pareti FI,Colli S,Tremoli E,Gallo L

    更新日期:2001-02-01 00:00:00

  • Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.

    abstract::Leukemia stem cells contribute to drug-resistance and relapse in chronic myeloid leukemia (CML) and BCR-ABL1 inhibitor monotherapy fails to eliminate these cells, thereby necessitating alternate therapeutic strategies for patients CML. The peroxisome proliferator-activated receptor-γ (PPARγ) agonist pioglitazone downr...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.194910

    authors: Kumar H,Chattopadhyay S,Das N,Shree S,Patel D,Mohapatra J,Gurjar A,Kushwaha S,Singh AK,Dubey S,Lata K,Kushwaha R,Mohammed R,Dastidar KG,Yadav N,Vishwakarma AL,Gayen JR,Bandyopadhyay S,Chatterjee A,Jain MR,Tripathi

    更新日期:2020-04-01 00:00:00

  • Multilineage engraftment of refrozen cord blood hematopoietic progenitors in NOD/SCID mice.

    abstract::Seven cord blood (CB) units were tested for their capacity to repopulate irradiated NOD/SCID mice after one or two successive cryopreservation procedures. In primary transplants with frozen or refrozen CB cells we observed equivalent human colonies and percentages of human CD45+ cells, with multilineage engraftment. I...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Timeus F,Crescenzio N,Sanavio F,Fazio L,Doria A,Foglia L,Pignochino Y,Berger M,Piacibello W,Madon E,Cordero di Montezemolo L,Fagioli F

    更新日期:2006-03-01 00:00:00

  • Aberrant expression of microRNA in polycythemia vera.

    abstract:BACKGROUND:Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis. Because microRNA regulate hematopoietic differentiation, we hypothesized that dysregul...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12706

    authors: Bruchova H,Merkerova M,Prchal JT

    更新日期:2008-07-01 00:00:00

  • Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in mice.

    abstract::Acquired aplastic anemia is an autoimmune-mediated bone marrow failure syndrome. The mechanism by which such an autoimmune reaction is initiated is unknown. Whether and how the genetic lesions detected in patients cause autoimmune bone marrow failure have not yet been determined. We found that mice with spontaneous de...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2016.151514

    authors: Xin J,Breslin P,Wei W,Li J,Gutierrez R,Cannova J,Ni A,Ng G,Schmidt R,Chen H,Parini V,Kuo PC,Kini AR,Stiff P,Zhu J,Zhang J

    更新日期:2017-02-01 00:00:00